Cordis' Cypher stent slightly more effective than Taxus stent, data shows

By Elaine Rigoli

Tampa, Fla., Sept. 5 - Cordis Corp. said Tuesday that patients who received the Cypher Sirolimus-eluting coronary stent were less prone to experience heart attacks (Q-wave myocardial infarctions) or blood clots (stent thromboses) than patients treated with Boston Scientific's Taxus stent, according to two-year data from a prospective, randomized, multi-center study.

The data showed that less than 1% of the patients in the Cypher stent arm experienced stent thrombosis. In contrast, 2.5% of the patients in the Taxus stent arm suffered a blood clot.

In addition, the Miami Lakes, Fla., medical-device company said patients treated with the Cypher stent suffered a Q-wave myocardial infarction (a heart attack affecting the full thickness of the heart wall) much less frequently than those receiving the Taxus stent (0.1% vs. 1.5%).

Other major adverse cardiac events were also tracked, but a composite of these did not show a statistical difference between the two drug-eluting stents.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.